Back to News
research

Chemed Corporation (CHE) Presents at Oppenheimer 36th Annual Healthcare MedTech & Services Conference Transcript

Seeking Alpha
Loading...
2 min read
0 likes
⚡ Quantum Brief
Chemed executives presented at Oppenheimer’s 2026 Healthcare Conference, with CEO Joel Wherley and CFO Michael Witzeman discussing financial guidance for their two divisions: VITAS Healthcare and Roto-Rooter. VITAS Healthcare’s guidance was deemed conservative, with potential upside from rebalancing patient mix toward more short-stay cases, aiming for improved profitability by year-end. Roto-Rooter’s outlook showed cautious optimism after recent underperformance, though past early-year guidance misses raise concerns about execution and seasonal volatility. Leadership emphasized operational adjustments in VITAS to stabilize revenue, while Roto-Rooter focuses on recovering from prior setbacks amid shifting market conditions. The fireside chat format allowed analysts to probe confidence levels, revealing strategic shifts in patient care and service delivery as key drivers for 2026 performance.
AI Audio Summary
0:00 / 0:00
Click to play
kevin-ku-w7ZyuGYNpRQ-unsplash.jpg
Quantum News · Media Library

SA Transcripts159.05K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Chemed Corporation (CHE) Oppenheimer 36th Annual Healthcare MedTech & Services Conference March 19, 2026 9:20 AM EDT Company Participants Michael Witzeman - Executive VP, Controller, Principal Accounting Officer & CFOJoel Wherley - President & CEO of VITAS Healthcare Conference Call Participants Michael Wiederhorn - Oppenheimer & Co. Inc., Research Division Presentation Michael WiederhornOppenheimer & Co. Inc., Research Division Welcome to Oppenheimer's 36th Annual Healthcare Conference. I'm Mike Wiederhorn, the health care analyst. It's our pleasure to introduce Chemed today, and we have Joel Wherley, President and CEO of VITAS; Mike Witzeman, Chief Financial Officer. Today will be a fireside. Thank you guys for joining us this morning. Let's just... Michael WitzemanExecutive VP, Controller, Principal Accounting Officer & CFO Hello, Mike. Question-and-Answer Session Michael WiederhornOppenheimer & Co. Inc., Research Division So I'll start right away, kind of kick in here. Can you discuss your guidance and your comfort level with each segment? I know it's a little open-ended, but we'll obviously get more into this, but just from a high-level perspective. Michael WitzemanExecutive VP, Controller, Principal Accounting Officer & CFO Yes. I'll start, and Joel can add some color at least on the VITAS side. I would say, if you break it down, we're very comfortable with the VITAS guidance. We think that there's probably some conservatism in it. We are working towards, as you know, balancing the patient mix, going back to a more balanced mix of short- and long-stay patients, and that provides some upward potential as we get through 2026. We're confident, fairly confident in the Roto-Rooter guidance. Obviously, the last couple of years have been a little rough there, and we've missed particularly the beginning of the year guidance by quite a bit by the time the end of the year comes. We feel like -- and I know we'll

Read Original

Tags

quantum-algorithms

Source Information

Source: Seeking Alpha

Discussion

0 professional contributions

Sign in to join this professional discussion.

Be the first to add a constructive contribution.